The influence of demographic factors and the duration of treatment with human recombinant growth hormone on satisfaction of parents with the treatment of children with somatotropin hypopituitarism
DOI:
https://doi.org/10.21784/IwP.2021.004Keywords
short stature, somatotropin hypopituitarism, parents satisfaction with growth hormone therapy, long-term therapy, demographic factorsAbstract
Introduction. The treatment of short stature caused by somatotropin hypopituitarism is a long process with serious restrictions and requirements. Administration of growth hormone in the form of daily injections, drug storage and follow-up visits are burdensome and require the involvement of the whole family in the treatment process. Not only the improvement in the child’s growth but also many other factors may affect the satisfaction of parents with the treatment effect.
Aim of the study. The aim of the study is to evaluate the influence of demographic factors and the duration of human growth hormone therapy on the satisfaction of parents with the treatment od children with somatotropin hypopituitarism.
Materiał and methods. The study involved 69 parents of children with somatotropin hypopituitarism treated with growth hormone at the Department of Paediatrics, Endocrinology, Diabetology and Paediatric Neurology at the Children’s Hospital in Torun. The research used the own questionnaire and KIDSCREEN questionnaire for parents.
Results and conclusions. The satisfaction with human growth hormone therapy depends on the child's growth results and is not affected by the long-term therapy. Parents' satisfaction with growth hormone treatment does not depend on the parents' education, place of residence or the child's sex. Research shows that satisfaction depends on the age of the child
Key words: short stature, somatotropin hypopituitarism, parents satisfaction with growth hormone therapy, long-term therapy, demographic factors.
References
Bednarczuk T. ITEM Publishing Podstawy endokrynologii, Warszawa 2017.
Hilczer M., Wskazania do leczenia hormonem wzrostu u dzieci i dorosłych, Przegląd Pediatryczny 2004;34,3/4.
Lewiński A. Ogólnopolski Program Leczenia Ciężkiego Niedoboru Hormonu Wzrostu u Osób Dorosłych oraz u Młodzieży po Zakończeniu Terapii Promującej Wzrastanie Endokrynologia Polska 2018;69,5.
Zbukiewicz-Kucharska A. Wpływ wybranych czynników na skuteczność leczenia GH u dzieci z somatotropinową niedoczynnością przysadki, Endokrynologia Pediatryczna 2014; 4(49). Vol.13.
Buczyńska-Górna M. Jakość życia u dzieci i młodzieży z somatotropinową niedoczynnością przysadki przed i w trakcie leczenia ludzki rekombinowanym hormonem wzrostu. Rozprawa doktorska napisana pod kierunkiem dr. hab. n. med. Andrzeja Kędzi 2009, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu.
Marini G.M., Stories of experiences of care for growth hormone deficiency: the CRESCERE project, Future Science OA /2016; vol. 2 nr 1.
Bielecka-Jasiocha J.. Psychospołeczne funkcjonowanie dzieci niskorosłych, Endokrynologia Pediatryczna , vol. 2008;7 nr 1(22).
Oleś M. Subiektywna jakość życia, poczucie własnej wartości i postrzegane wsparcie społeczne u nastolatków z zaburzeniami endokrynnymi. Endokrynologia Pediatryczna 2014;13:35–48.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Lech Grzelak, Anna Wiśniewska, Robert Ślusarz
![Creative Commons License](http://i.creativecommons.org/l/by-nc-nd/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Stats
Number of views and downloads: 260
Number of citations: 0